- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04916886
A Clinical Trial of Immunobridging and Lot-to-lot Consistency of COVID-19 Vaccine (Ad5-nCoV) in Different Age Groups.
February 7, 2023 updated by: CanSino Biologics Inc.
To Evaluate the Immunogenicity Bridging Between Different Manufacture Scales and Between Different Lots of Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV) in Population 6-59 Years of Age.
The study is a single-center, randomized and double-blinded trial to evaluate the immunobridging between different manufacture scales, lot-to-lot consistency of the Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)(Ad5-nCOV) in population 6-59 years of age.
The immunobridging between different manufacture scales will be evaluated first, the immunobridging between different age groups will be evaluated second, the lot-to-lot consistency will be evaluated at last.
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
2021
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Jiangsu
-
Yancheng, Jiangsu, China
- Funing Center for Disease Control and Prevention
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
6 years to 59 years (ADULT, CHILD)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 6-59 years of age at the time of enrollment;
- Able to provide consent or obtain consent from guardian to participate in the trial and sign an Informed Consent Form (ICF);
- Able and willing to complete all the scheduled study procedures during the whole study follow-up period;
- Axillary temperature ≤37.0℃;
- IgG ang IgM negative for Covid-19;
- Have not received any type of Covid-19 vaccines;
- No contact history of Covid-19; no travel history to medium and high risk regions and abroad in the past 21 days;
- Participants who are clinically determined to be healthy after checking medical history and physical examination are eligible to receive the product.
Exclusion Criteria:
- Medical or family history of convulsions, epilepsy, encephalopathy, and psychosis disorders;
- History of allergies to any ingredient of Ad5-nCoV, history of serious allergic reactions to any vaccine, history of allergies and immune diseases;
- Women who are pregnant or lactating, positive urine pregnancy test or plan to become pregnant during the 12 months study period;
- Acute febrile diseases and infectious diseases, medical history of SARS (SARS-CoV-1);
- Serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial infarction, severe hypertension and uncontrollable medications (on-site measurement for 18-59 years of age: systolic blood pressure ≥160mmHg, diastolic blood pressure ≥100mmHg), etc;
- Severe chronic diseases or with advanced stage conditions which cannot be controlled smoothly, such as diabetes, thyroid disease, etc;
- Congenital or acquired angioedema/neurological edema;
- Urticaria history within 1 year before receiving the study vaccine;
- Asplenia or functional aspleenia;
- Thrombocytopenia or other coagulation disorders (may cause contraindications for intramuscular injection);
- Trypanophobia;
- History of receiving immunosuppressant therapy, anti-allergic therapy, cytotoxic therapy, nebulized corticosteroid therapy in the past 6 months (not including corticosteroid spray treatment for allergic rhinitis, and surface corticosteroid treatment for acute non-complicated dermatitis);
- Prior administration of blood products in last 4 months;
- Received other investigational drugs within 1 month before the study;
- Prior administration of live attenuated vaccines within 1 month before the study;
- Prior administration of subunit or inactivated vaccines within 14 days before the study;
- Current anti-tuberculosis therapy;
- Medical history of Covid-19 disease/infection;
- Any condition that in the opinion of the investigators may interfere with the participants' compliance or evaluation of study objectives or informed consent (i.e. medical, psychological, social or other conditions, etc.).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: 50L Scale (Age 18-59)
Single dose of 0.5ml Ad5-nCoV containing 0.5E10 vp.
|
Containing 0.5E10vp
|
EXPERIMENTAL: 500L Scale (Age 18-59)
Single dose of 0.5ml Ad5-nCoV containing 0.5E10 vp.
|
Containing 0.5E10vp
|
EXPERIMENTAL: 800L Scale (Age 18-59)
Single dose of 0.5ml Ad5-nCoV containing 0.5E10 vp.
|
Containing 0.5E10vp
|
EXPERIMENTAL: 800L Scale Lot 1 (Age 13-17)
Single dose of 0.3ml Ad5-nCoV containing 0.3E10 vp.
|
Containing 0.3E10vp
|
EXPERIMENTAL: 800L Scale Lot 2 (Age 13-17)
Single dose of 0.3ml Ad5-nCoV containing 0.3E10 vp.
|
Containing 0.3E10vp
|
EXPERIMENTAL: 800L Scale Lot 3 (Age 13-17)
Single dose of 0.3ml Ad5-nCoV containing 0.3E10 vp.
|
Containing 0.3E10vp
|
EXPERIMENTAL: 800L Scale Lot 1 (Age 6-12)
Single dose of 0.3ml Ad5-nCoV containing 0.3E10 vp.
|
Containing 0.3E10vp
|
EXPERIMENTAL: 800L Scale Lot 2 (Age 6-12)
Single dose of 0.3ml Ad5-nCoV containing 0.3E10 vp.
|
Containing 0.3E10vp
|
EXPERIMENTAL: 800L Scale Lot 3 (Age 6-12)
Single dose of 0.3ml Ad5-nCoV containing 0.3E10 vp.
|
Containing 0.3E10vp
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
GMT of anti SARS-CoV-2 specific neutralizing antibody
Time Frame: 28 days after vaccination
|
GMT of anti SARS-CoV-2 specific neutralizing antibody in all groups (wild type variants test).
|
28 days after vaccination
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Seroconversion rate of SARS-CoV-2 neutralizing antibody
Time Frame: 28 days after vaccination
|
Seroconversion rate of anti SARS-CoV-2 specific neutralizing antibody (wild type variants test).
|
28 days after vaccination
|
GMI of SARS-CoV-2 neutralizing antibody
Time Frame: 28 days after vaccination
|
GMI of anti SARS-CoV-2 specific neutralizing antibody (wild type variants test).
|
28 days after vaccination
|
GMT of SARS-CoV-2 S protein RBD antibody
Time Frame: 28 days after vaccination
|
GMT of SARS-CoV-2 S protein RBD antibody measured by ELISA in all groups
|
28 days after vaccination
|
Seroconversion rate of SARS-CoV-2 S protein RBD antibody
Time Frame: 28 days after vaccination
|
Seroconversion rate of SARS-CoV-2 S protein RBD antibody measured by ELISA in all groups.
|
28 days after vaccination
|
GMI of SARS-CoV-2 S protein RBD antibody
Time Frame: 28 days after vaccination
|
GMI of SARS-CoV-2 S protein RBD antibody measured by ELISA in all groups.
|
28 days after vaccination
|
GMT of Ad5 vector neutralizing antibody
Time Frame: 28 days after vaccination
|
GMT of anti Ad5 vector neutralizing antibody responses post vaccination in all groups
|
28 days after vaccination
|
GMI of Ad5 vector neutralizing antibody
Time Frame: 28 days after vaccination
|
GMI of Ad5 vector neutralizing antibody responses post vaccination in all groups
|
28 days after vaccination
|
Stratified analysis on Ad5 vector neutralizing antibody
Time Frame: 28 days after vaccination
|
Stratified analysis based on the GMT of Ad5 vector neutralizing antibody responses post vaccination.
|
28 days after vaccination
|
Incidence of Adverse Reactions/Events (AE/AR)
Time Frame: Within 30 minutes after vaccination
|
The occurance of Adverse Reactions/Events within 30 minutes post vaccination
|
Within 30 minutes after vaccination
|
Incidence of Adverse Reactions/Events (AE/AR)
Time Frame: Within 0-7 days after vaccination
|
The occurance of Adverse Reactions/Events (AE/AR) within 7 days post vaccination.
|
Within 0-7 days after vaccination
|
Incidence of Adverse Reactions/Events (AE/AR)
Time Frame: Within 0-28 days after vaccination
|
The occurance of Adverse Reactions/Events (AE/AR) within 28 days post vaccination.
|
Within 0-28 days after vaccination
|
Incidence of Serious Adverse Events (SAE)
Time Frame: Within 12 months after vaccination
|
Occurance of Serious Adverse Events (SAE) post vaccination.
|
Within 12 months after vaccination
|
Incidence of Adverse Events of Special Interest (AESI)
Time Frame: Within 12 months after vaccination
|
Occurance of Adverse Events of Special Interest (AESI) post vaccination.
|
Within 12 months after vaccination
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
June 3, 2021
Primary Completion (ACTUAL)
July 31, 2022
Study Completion (ACTUAL)
July 31, 2022
Study Registration Dates
First Submitted
May 30, 2021
First Submitted That Met QC Criteria
June 4, 2021
First Posted (ACTUAL)
June 8, 2021
Study Record Updates
Last Update Posted (ACTUAL)
February 8, 2023
Last Update Submitted That Met QC Criteria
February 7, 2023
Last Verified
October 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- JSVCT118
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
First Affiliated Hospital Xi'an Jiaotong UniversityShangluo Central Hospital; Ankang Central Hospital; Hanzhong Central Hospital; Yulin... and other collaboratorsRecruitingCOVID-19 | Post-COVID-19 Syndrome | Post-Acute COVID-19 | Acute COVID-19China
Clinical Trials on Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.5ml
-
CanSino Biologics Inc.Jiangsu Province Centers for Disease Control and Prevention; Beijing Institute...Completed
-
CanSino Biologics Inc.Tongji Hospital; Jiangsu Province Centers for Disease Control and Prevention; Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China and other collaboratorsCompleted
-
NPO PetrovaxCanSino Biologics Inc.Active, not recruitingCovid19Russian Federation
-
CanSino Biologics Inc.Beijing Institute of BiotechnologyCompletedCOVID-19Mexico, Argentina, Chile, Pakistan, Russian Federation
-
CanSino Biologics Inc.Beijing Institute of Biotechnology; Canadian Center for VaccinologyUnknown
-
Fundación HuéspedCanSino Biologics Inc.; Canadian Center for Vaccinology; Hospital FernandezRecruiting
-
Institute of Biotechnology, Academy of Military...Zhongnan Hospital; Jiangsu Province Centers for Disease Control and Prevention and other collaboratorsCompleted
-
CanSino Biologics Inc.Beijing Institute of BiotechnologyTerminated
-
CanSino Biologics Inc.Jiangsu Province Centers for Disease Control and Prevention; Beijing Institute...Completed